|
1) Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155: 1151-64
|
|
|
|
2) Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective. Euro J Immunol. 2007; 37(Suppl 1): S116-23
|
|
|
|
|
|
3) Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, N. Y). 2003; 299: 1057-61
|
|
|
|
|
4) Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000; 106: R75-81
|
|
|
|
|
|
5) Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature genetics. 2001; 27: 18-20
|
|
|
|
|
|
6) Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature genetics. 2001; 27: 20-1
|
|
|
|
|
|
7) Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature genetics. 2001; 27: 68-73
|
|
|
|
|
|
8) Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007; 13: 108-16
|
|
|
|
|
|
9) Wu AJ, Hua H, Munson SH, et al. Tumor necrosis factor-alpha regulation of CD4＋CD25＋ T cell levels in NOD mice. Proc Natl Acad Sci U S A. 2002; 99: 12287-92
|
|
|
|
|
|
10) Kohm AP, Carpentier PA, Anger HA, et al. Cutting edge: CD4＋CD25＋ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol. 2002; 169: 4712-6
|
|
|
|
|
|
11) Hori S, Haury K, Coutinho A, et al. Specificity requirements for selection and effector functions of CD25＋CD4＋ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2002; 99: 8213-8
|
|
|
|
|
|
12) Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(＋)CD25(＋) T-cells from patients with type 1 diabetes. Diabetes. 2005; 54: 92-9
|
|
|
|
|
|
13) Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4＋CD25＋ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971-9
|
|
|
|
|
|
14) Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med. 2004; 200: 277-85
|
|
|
|
|
|
15) Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003; 21: 273-6
|
|
|
|
|
|
16) Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96: 2049-54
|
|
|
|
|
|
17) Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000; 95: 1931-4
|
|
|
|
|
|
18) Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol. 2000; 37: 3-14
|
|
|
|
|
|
19) Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002; 100: 1185-91
|
|
|
|
|
|
20) Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006; 107: 3983-91
|
|
|
|
|
|
21) Risitano AM, Maciejewski JP, Green S, et al. In vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004; 364: 355-64
|
|
|
|
|
|
22) Chen J, Ellison FM, Eckhaus MA, et al. Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol. 2007; 178: 4159-68
|
|
|
|
|
|
23) Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4＋ CD25＋ FOXP3＋ T regulatory cells in acquired aplastic anemia. Blood. 2007; 110: 1603-6
|
|
|
|
|
|
24) Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4＋CD25highFOXP3＋ regulatory T cells in vitro. Blood. 2008; 111: 3675-83
|
|
|
|
|